Strategic targeting of AckA in Mycobacterium tuberculosis using peptide inhibitors
- PMID: 40844623
- DOI: 10.1007/s00203-025-04439-4
Strategic targeting of AckA in Mycobacterium tuberculosis using peptide inhibitors
Abstract
Tuberculosis (TB) continues to pose a significant global health challenge, exacerbated by the rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, which undermine the efficacy of existing therapies. Recent research focuses on anti-tubercular peptides as promising therapeutics due to their direct antimicrobial action and ability to enhance antibiotic efficacy by disrupting mycobacterial membranes. This study aims to identify and characterize potent anti-tubercular peptides targeting Acetate Kinase (AckA), a key enzyme in the metabolism of Mycobacterium tuberculosis. Through peptide virtual screening (PVS), followed by evaluations of cell penetration, toxicity, and MM/GBSA binding energy calculations, we identified five potential lead peptides, namely, DBAASP4864, DBAASP17881, DBAASP7096, DBAASP1043, and DBAASP5585, sourced from curated antimicrobial peptide databases (APD3, DBAASP, DRAMP, AntiTb, SATPdb, and CAMPR3). These candidates were selected based on favorable physicochemical properties, minimal toxicity, and strong binding affinities. Molecular dynamics simulations (MDS) demonstrated the structural stability of the peptide AckA complexes, with increased hydrogen bond formation observed over the simulation trajectories. Further validation through principal component analysis (PCA) and free energy landscape (FEL) mapping revealed a dominant low-energy basin, supporting the conformational stability of the complexes. MM/PBSA analysis confirmed strong binding interactions, and key residues, namely, Asn195, Asp266, Phe267, Gly314, and Asn318, were identified as critical contributors to peptide binding and complex stabilization. The study reveals peptide dynamics, highlighting their therapeutic potential and clinical applicability, while providing a strong foundation for experimental validation and developing next-generation anti-tubercular agents targeting drug-sensitive and drug-resistant M. tuberculosis strains.
Keywords: Acetate kinase; MDR/XDR tuberculosis; Molecular dynamics; Peptide inhibitors; Peptide virtual screening.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical approval and consent to participate: Not applicable. Conflict of interest: The authors declare no competing interests.
Similar articles
-
Suppressing lipid biosynthesis in Mycobacterium tuberculosis through polyketide synthase 13 thioesterase inhibition: Insights from computational analysis.J Infect Public Health. 2025 Sep;18(9):102835. doi: 10.1016/j.jiph.2025.102835. Epub 2025 May 26. J Infect Public Health. 2025. PMID: 40460691
-
Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant Mycobacterium tuberculosis.mBio. 2025 Aug 13;16(8):e0137225. doi: 10.1128/mbio.01372-25. Epub 2025 Jul 10. mBio. 2025. PMID: 40637416 Free PMC article.
-
Determining the effect of natural compounds on mutations of pyrazinamidase in multidrug-resistant tuberculosis: Illuminating the dark tunnel.Biochem Biophys Res Commun. 2025 Apr 5;756:151575. doi: 10.1016/j.bbrc.2025.151575. Epub 2025 Mar 6. Biochem Biophys Res Commun. 2025. PMID: 40064092
-
The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs.Cochrane Database Syst Rev. 2014 Oct 29;(10):CD010705. doi: 10.1002/14651858.CD010705.pub2. Cochrane Database Syst Rev. 2014. PMID: 25353401 Free PMC article.
-
Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.Cochrane Database Syst Rev. 2022 Apr 26;4(4):CD014877. doi: 10.1002/14651858.CD014877.pub2. Cochrane Database Syst Rev. 2022. PMID: 35470432 Free PMC article.
References
-
- Adasme MF, Linnemann KL, Bolz SN et al (2021) PLIP 2021: expanding the scope of the protein–ligand interaction profiler to DNA and RNA. Nucleic Acids Res 49:W530–W534. https://doi.org/10.1093/nar/gkab294 - DOI - PubMed - PMC
-
- Agrawal P, Bhalla S, Usmani SS et al (2016) CPPsite 2.0: a repository of experimentally validated cell-penetrating peptides. Nucleic Acids Res 44:D1098–D1103. https://doi.org/10.1093/nar/gkv1266 - DOI - PubMed
-
- Ahmad S, Bano N, Raza K (2025a) RCSB protein data bank: revolutionising drug discovery and design for over five decades. Med Data Min 8:8. https://doi.org/10.53388/MDM202508008 - DOI
-
- Ahmad S, Bano N, Raza K (2025b) Evaluating the polypharmacological potency of FEDPN from chembl bioassays against lung cancer EGFR, ALK, TrkA and KRAS proteins. Int J Biol Macromol 306:141703. https://doi.org/10.1016/j.ijbiomac.2025.141703 - DOI - PubMed
-
- Ansar S, Vetrivel U (2019) PepVis: an integrated peptide virtual screening pipeline for ensemble and flexible Docking protocols. Chem Biol Drug Des 94:2041–2050. https://doi.org/10.1111/cbdd.13607 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous